[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334845-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334845-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","anticancer-drugs-related-hypogonadism-in-male-patients-with-advanced-cancers-on-active-treatment-a-systematic-review","Anticancer Drugs-Related Hypogonadism in Male Patients with Advanced Cancers on Active Treatment - A Systematic Review","","Background: In male cancer patients treated with antineoplastic drugs, hypogonadism contributes to diminished quality of life yet remains underrecognized. The condition may reflect cancer-related factors and/or treatment toxicity, and the specific role of anticancer drugs is insufficiently defined. Objective: This systematic review aimed to determine the prevalence, character (primary vs secondary), and quality-of-life impact of hypogonadism among men receiving antineoplastic therapy. Methods: PubMed, Embase, and Cochrane searches selected English-language studies from 1945 to February 28, 2023.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/anticancer-drugs-related-hypogonadism-in-male-patients-with-advanced-cancers-on-active-treatment-a-systematic-review/334845/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/anticancer-drugs-related-hypogonadism-in-male-patients-with-advanced-cancers-on-active-treatment-a-systematic-review/334845.png","ImageObject",300,407,{"name":42,"@type":43},"Ivy","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the purpose of this systematic review?","Question",{"text":63,"@type":64},"To determine the prevalence, primary/secondary nature, and quality-of-life impact of hypogonadism in male patients with cancer receiving antineoplastic therapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which databases and time range were used for the literature search?",{"text":68,"@type":64},"PubMed, Embase, and Cochrane were searched, covering publications from January 1, 1945 to February 28, 2023.",{"name":70,"@type":61,"acceptedAnswer":71},"What anticancer therapies were linked to different types of hypogonadism?",{"text":72,"@type":64},"Antiangiogenic drugs and crizotinib were associated with development of hypogonadism; immune checkpoint inhibitors were linked to secondary hypogonadism via immune-related hypophysitis or orchitis; platinum salts were often associated with hypogonadism among active chemotherapy regimens.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334845,1790293721,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","Anticancer Drugs-Related Hypogonadism in Male Patients with Advanced Cancers on Active Treatment: A Systematic Review  \nGiacomo Massa1,‡, Luca Zambelli2,‡, Ernesto Zecca*, 1,, Morena Shkodra1, Gabriele Tinè3, Augusto Caraceni1,4  \n1 Palliative Care, Pain Therapy and Rehabilitation Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy 2Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy  \n3 Biostatistic for Clinical Research Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy 4Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milano, Italy  \n* Corresponding author: Ernesto Zecca, Palliative Care, Pain Therapy, and Rehabilitation Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy. Tel: +39390223902083; Fax: +39390223903393. Email: ernesto.zecca@istitutotumori. mi. it  \n‡Contributed equally  \nAbstract  \nBackground: In male patients with cancer treated with antineoplastic drug, hypogonadism is a neglected cause of diminished quality of life. This condition may be cancer related as well as toxicity related. The role of antineoplastic drug in causing hypogonadism is poorly understood. The aim of this systematic review was to establish the prevalence, nature (primary/secondary), and impact of hypogonadism on quality of life in male patients with cancer on antineoplastic therapy.  \nMethods: The search strategy used PubMed, Embase, and Cochrane databases to select articles in English language that described hypogonadism in male patients with cancer. The search period was from January 1, 1945 to February 28, 2023. We included observational studies, case reports or case series and excluded studies concerning hematological malignancies, prostate cancer, female patients, and survivors .  \nFindings: Of 4488 records identified, 28 studies met inclusion criteria (17 observational studies, 11 case reports or case series) . Antiangiogenic drugs and crizotinib were found to have a role in the development of hypogonadism. Patients treated with immune checkpointinhibitors developed secondary hypogonadism due to immune-related hypophysitis or orchitis. As for active chemotherapy, platinum salts were often associated with hypogonadism, followed by antimetabolites and taxanes . Selected studies were heterogeneous for populations, interventions, and outcomes assessments. Thus, a generalization is difficult. Moreover, the role of concurrent etiologies cannot be excluded in most studies.  \nConclusion: Our research emphasizes the importance of evaluating the gonadal axis before treatment in patients considered at risk and testing it at regular intervals or in case of clinical suspicion.  \nKey words: male hypogonadism; anti-cancer therapy toxicity; testosterone; chemotherapy; immunotherapy; targeted therapy.  \nImplications for Practice  \nThis review highlights the occurrence of male hypogonadism as a possible anti-cancer treatment toxicity, even if the quality of evidence is still low. As such, it could be useful to develop trial to better understand this adverse event. In clinical practice, it could be useful to evaluate gonadal axis before treatment at risk and in case of typical symptoms, since testosterone replacement therapy may be beneficial in these patients.  \nIntroduction  \nThe improvement of anticancer strategies and the increasing number of therapeutic options such as chemotherapy, targeted therapies, and immune checkpoint-inhibitors, resulted in the last decade in an increased survival in patients with advanced or metastatic cancer.1,2 There is a growing consensus  \nthat, in these patients, quality of life (QoL), together with survival, should be considered as clinical outcomes and that QoL can be influenced by both the disease and anticancer treatment effects. Male hypogonadism is a possible, though neglected, cause of diminished QoL associated with cancer and its treatments.3,4 Wh","cbCaiosIYkbPvGJr","https://ap.wps.com/l/cbCaiosIYkbPvGJr","pdf",4208596,13,"English","# Abstract\n## Background\n## Methods\n## Findings\n## Conclusion\n# Implications for Practice\n# Introduction\n# Methods","[{\"question\":\"What was the purpose of this systematic review?\",\"answer\":\"To determine the prevalence, primary/secondary nature, and quality-of-life impact of hypogonadism in male patients with cancer receiving antineoplastic therapy.\"},{\"question\":\"Which databases and time range were used for the literature search?\",\"answer\":\"PubMed, Embase, and Cochrane were searched, covering publications from January 1, 1945 to February 28, 2023.\"},{\"question\":\"What anticancer therapies were linked to different types of hypogonadism?\",\"answer\":\"Antiangiogenic drugs and crizotinib were associated with development of hypogonadism; immune checkpoint inhibitors were linked to secondary hypogonadism via immune-related hypophysitis or orchitis; platinum salts were often associated with hypogonadism among active chemotherapy regimens.\"}]","Anticancer Drugs-Related Hypogonadism in Male Patients with Advanced Cancers on Active Treatment - A Systematic Review | PDF",1790008533,33]